title: Measuring Toxicity in Phase I Clinical Trials--Letter.
authors.affiliation: Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Medicine, Weill Cornell Medical College, New York, New York. hymand@mskcc.org.
authors.forename: David M
authors.initials: DM
authors.lastname: Hyman
authors.affiliation: Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Anne
authors.initials: A
authors.lastname: Eaton
authors.affiliation: Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.
authors.forename: S Percy
authors.initials: SP
authors.lastname: Ivy
authors.affiliation: Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Department of Medicine, Weill Cornell Medical College, New York, New York.
authors.forename: David R
authors.initials: DR
authors.lastname: Spriggs
authors.affiliation: Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Alexia
authors.initials: A
authors.lastname: Iasonos
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents